Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin’s Gupta Moves Up To Lead IGBA Leadership Committee

Replaces Sandoz CEO Saynor As Chair, While Insud CEO Sigman Becomes Vice-Chair For 2024

Executive Summary

Lupin CEO Vinita Gupta will next year take over from Sandoz chief executive Richard Saynor as chair of the IGBA’s CEO advisory committee, representing the voice of the global off-patent industry. At the same time, Insud CEO Lucas Sigman will take over from Gupta as vice-chair.

You may also be interested in...



IGBA Appoints New Secretary General As Kox Steps Down

Inaugural IGBA secretary general Suzette Kox has stepped down from the role after five years, passing leadership of the organization to Susana Almeida. At the same time, Medicines for Europe director general Adrian van den Hoven has taken up the position of IGBA chair for 2024.

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

IGBA And WHO Ally On Access Ambitions

IGBA representatives have met with the WHO director general to build on efforts to expand global access to generics and biosimilars.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel